Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b

Digestive and Liver Disease

Volumn 37, Issue 11, 2005, Pages 882-885

  Venezia, G ^a   Licata, A ^a   Di Marco, V ^a   Craxi A ^a   Almasio, P L ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acute hepatitis C; Hepatitis C virus; IFN; Polymyositis

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2B; ALPHA2A INTERFERON; ANTIVIRUS AGENT; CREATINE KINASE; DRUG CARRIER; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE WEAKNESS; NONHUMAN; PHYSICAL EXAMINATION; POLYMYOSITIS; ACUTE DISEASE; AUTOIMMUNITY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED;

ACUTE DISEASE; ANTIVIRAL AGENTS; AUTOIMMUNITY; CREATINE KINASE; DRUG CARRIERS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMYOSITIS; RNA, VIRAL;

EID: 33644875653     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.06.010     Document Type: Article

References (37)

1. Marcellin P. Hepatitis C, clinical spectrum of the disease. J Hepatol 31 Suppl. 1 (1999) 9-16
2. Orland J.R., Wright T.L., and Cooper S. Acute hepatitis C. Hepatology 33 (2001) 321-327
3. Santantonio T., Sinisi E., Guastadisegni A., Casalino C., Mazzola M., Gentile A., et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 35 (2003) 104-113
4. Hu K.Q., and Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999) 1311-1316
5. Cammà C., Almasio P., and Craxì A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 41 (1996) 1248-1255
6. Thevenot T., Regimbeau C., Ratziu V., Leroy V., Opolon P., and Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 8 (2001) 48-62
7. Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, Mathurin P, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002;(1):CD000369.
8. Licata A., Di Bona D., Schepis F., Shahied L., Craxì A., and Camma C. When and how to treat acute hepatitis C?. J Hepatol 39 (2003) 1056-1062
9. Viladomiu L., Genesca J., Esteban J.I., Allende H., Gonzalez A., Lopez-Talavera J.C., et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 15 (1992) 767-769
10. Tassopoulos N.C., Koutelou M.G., Papatheodoridis G., Polychronaki H., Delladetsima I., Giannikakis T., et al. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut 34 (1993) S130-S132
11. Palmovic D., Kurelac I., and Crnjakovic-Palmovic J. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha. Infection 22 (1994) 222-223
12. Hwang S.J., Lee S.D., Chan C.Y., Lu R.H., and Lo K.J. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 21 (1994) 831-836
13. Calleri G., Colombatto P., Gozzelino M., Chieppa F., Romano P., Delmastro B., et al. Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 30 (1998) 181-184
14. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
15. Fried M.W., Shiffman M.L., Reddy R.K., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
16. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) S237-S244
17. Dalakas M.C., and Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 (2003) 971-982
18. Satoh J., Eguchi Y., Narukiyo T., Mizuta T., Kobayashi O., Kawai M., et al. Necrotizing myopathy in a patient with chronic hepatitis C virus infection: a case report and a review of the literature. Intern Med 39 (2000) 176-181
19. Sola P., Galassi G., Merelli E., Ferrari M.G., Sorgato P., and Ghini M. Detection of HCV-specific sequences in chronic myopathy with hepatitis C: improvement with interferon-alpha 2A therapy. Eur Neurol 42 (1999) 181-183
20. Di Muzio A., Bonetti B., Capasso M., Panzeri L., Pizzigallo E., Rizzuto N., et al. Hepatitis C virus infection and myositis: a virus localization study. Neuromuscul Disord 13 (2003) 68-71
21. Horsmans Y., and Geubel A.P. Symptomatic myopathy in hepatitis C infection without interferon therapy. Lancet 345 (1995) 1236
22. Alric L., Partensky J., Reynaud D., Rauzy O., and Duffaut M. Association between polymyositis and hepatitis C infection. Treatment-related difficulties. Rev Med Interne 21 (2000) 542-546
23. Dietrich L.L., Bridges A.J., and Albertini M.R. Dermatomyositis after interferon alpha treatment. Med Oncol 17 (2000) 64-69
24. Kalkner K.M., Ronnblom L., Karlsson Parra A.K., Bengtsson M., Olsson Y., and Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 91 (1998) 393-399
25. Matsuya M., Abe T., Tosaka M., Yonezawa K., Ono A., Ikeda N., et al. The first case of polymyositis associated with interferon therapy. Intern Med 33 (1994) 806-808
26. Schleinitz N., Veit V., Labarelle A., Figarella-Branger D., and Harle J.R. Polymyositis: a rare complication of interferon alpha therapy. Rev Med Interne 21 (2000) 113-114
27. Lee S.W., Kim K.C., Oh D.H., Jung S.S., Yoo D.H., Kim S.Y., et al. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. J Korean Med Sci 17 (2002) 141-143
28. Cirigliano G., Della Rossa A., Tavoni A., Viacava P., and Bombardieri S. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 19 (1999) 65-67
29. Arai H., Tanaka M., Ohta K., Kojo T., Niijima K., and Imawari M. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet 345 (1995) 582
30. Sato Y., Takatsu Y., Yamada T., Kataoka K., Taniguchi R., Mimura R., et al. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J 64 (2000) 321-324
31. Falcone A., Bodenizza C.A., Musto P., and Carotenuto M. Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukaemia. Leukemia 12 (1998) 1329
32. Iguchi H., Kishi M., Fujioka T., Wakata N., and Kinoshita M. Polymyositis after interferon beta treatment of chronic hepatitis type C. Rinsho Shinkeigaku 36 (1996) 22-24
33. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 25 (2003) 80-88
34. Dumoulin F.L., Leifeld L., Sauerbruch T., and Spengler U. Autoimmunity induced by interferon-α therapy for chronic viral hepatitis. Biomed Pharmacother 53 (1999) 242-254
35. Kuru S., Inukai A., Liang Y., Doyu M., Takano A., and Sobue G. Tumornecrosis factor-α expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99 (2000) 585-588
36. Golstein P.E., Delforge M.L., Deviere J., and Marcellin P. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. J Viral Hepat 11 (2004) 183-186
37. Curry M.P., Robinson S.C., Savitz S., Williams C., and Gitlin N. Elevated ALT and AST due to pegylated interferon -α induced polymyositis in treated patients with undetectable hepatitis C viral load. Hepatology 40 Suppl. 1 (2004) 344A